Where does Jiangsu Hansoh Pharmaceutical Group Co., Ltd rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Jiangsu Hansoh Pharmaceutical Group Co., Ltd ranks #11,302 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Jiangsu Hansoh Pharmaceutical Group Co., Ltd hold?

Jiangsu Hansoh Pharmaceutical Group Co., Ltd holds 27 US utility patents granted between 2015 and 2025, spanning 11 technology areas.

What is Jiangsu Hansoh Pharmaceutical Group Co., Ltd's Innovation Score?

Jiangsu Hansoh Pharmaceutical Group Co., Ltd has an Innovation Score of 37.1 out of 100 (top 44% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Jiangsu Hansoh Pharmaceutical Group Co., Ltd focus on?

Jiangsu Hansoh Pharmaceutical Group Co., Ltd's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 26 patents, ranking #760 of 6,058 assignees active in that subclass. Grants appear in 11 CPC subclasses total.

Is Jiangsu Hansoh Pharmaceutical Group Co., Ltd's patent grant rate increasing or decreasing?

Jiangsu Hansoh Pharmaceutical Group Co., Ltd's recent grant velocity is -27% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Jiangsu Hansoh Pharmaceutical Group Co., Ltd's patents?

Jiangsu Hansoh Pharmaceutical Group Co., Ltd's patents average 15.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Jiangsu Hansoh Pharmaceutical Group Co., Ltd

Q: How is the Jiangsu Hansoh Pharmaceutical Group Co., Ltd patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO PatentsView assignee record - 27 granted patents across 11 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Jiangsu ranks #11,302 of 49,997 tracked US assignees by granted-patent volume, with 27 patents across 11 technology areas.

#11,302
of 49,997 US assignees by volume: Top 44%
by Innovation Score (37.1/100): 15.7
avg claims per patent: -27%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R11302 · Foreign Corporation #11,302 · 27 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-SMALL 27 grants
UPPER-Q #11,302/49,997
PHOTO-FINISH Innovative Building
CPC-FOCUS A61P · 11 areas
INNOV-THIN 37.1/100
CLAIMS-RICH 15.7 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -27% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Innovative Building Technologies, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Jiangsu’s 37.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.5 pts (31%) Velocity 4.4 pts (12%) Breadth 11.7 pts (32%) Claim depth 9.4 pts (25%)

Qualcomm Incorporated · highest

85
Allied Bioscience · near

37
Calgary Scientific · near

37
Jiangsu Hansoh… · this assignee

37
Johnson Matthey… · near

37
Kawai Gakki Seisakusho · near

37
3D Lighting… · lowest

7

What this shows Jiangsu's Innovation Score is 37.1/100 (top 44% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Jiangsu?

Each dot is one of Jiangsu’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Jiangsu’s own 15.7 claims/patent is at or below the 15.9 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Jiangsu vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Jiangsu's grants concentrate

Jiangsu Hansoh Pharmaceutical Group Co., Ltd is a focused PatentsView assignee: 11 CPC subclasses with 96.3% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2016 (5 grants) versus a trough of 1 in 2018. By volume, Jiangsu sits between Innovative Building Technologies, LLC and KIP CR P1 LP.

Jiangsu's three-year grant acceleration

Jiangsu Hansoh Pharmaceutical Group Co., Ltd shows 6 grants in 2022–2024 against only 9 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Innovative Buildi…

27
Intelligent Agric…

27
Interactive Memor…

27
Interwise

27
Jeju National Uni…

27
Jiangsu Favored N…

27
Joingo

27
KIP CR P1

27
Jiangsu Hansoh Ph… ◀

27

What this shows Jiangsu holds 27 patents at rank #11,298, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Jiangsu

By rank, the assignees closest to #11,298 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Jiangsu's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Jiangsu, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Jiangsu ranks #760 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (37 here).

Allied Bioscience, Inc. 37 Johnson Matthey Fuel Cells Limited 37 Kabushiki Kaisha Kawai Gakki Seisakusho 37 Calgary Scientific Inc. 37

Jiangsu's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

37 Top 44% higher than 56% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Jiangsu Hansoh Pharmaceutical Group Co., Ltd patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	7.4%
2016	5	18.5%
2017	3	11.1%
2018	1	3.7%
2019	4	14.8%
2020	3	11.1%
2021	2	7.4%
2022	1	3.7%
2023	4	14.8%
2024	1	3.7%
2025partial year	1	3.7%

Which technologies does Jiangsu Hansoh Pharmaceutical Group Co., Ltd patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 26

C07D - Heterocyclic Compounds 18

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 17

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 8

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 5

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 4

C07C - Acyclic OR Carbocyclic Compounds 3

C07J - Steroids 2

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 2

C07K - Peptides 2

B82Y - Specific Uses OR Applications OF NANOSTRUCTURES; Measurement OR Analysis OF NANOSTRUCTURES; Manufacture OR Treatment OF Nanostructures 1

Top 11 of 11 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Jiangsu Hansoh Pharmaceutical Group Co., Ltd's patent record in context - here's where to go next.

Jiangsu Hansoh Pharmaceutical Group Co., Ltd's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 96.3% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #11,302 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Jiangsu Hansoh Pharmaceutical Group Co., Ltd against Innovative Building Technologies, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 37.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.